Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to LeonaBio, Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and none in 2023
Applications published
12
6 of them in 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Athira Pharma, Inc. a former name
US, as the owner printed on each patent
11 publishedM3 BIOTECHNOLOGY, INC. a former name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 23, 2025 | 12,421,276 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | Pharmaceuticals | Athira Pharma, Inc. |
| Jun 4, 2024 | 11,998,556 | Methods of treating parkinson's disease and/or lewy body disease or disorder(s) | Pharmaceuticals | Athira Pharma, Inc. |
| Jun 1, 2021 | 11,021,514 | Compounds | Pharmaceuticals | Athira Pharma, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 18, 2025 | 2025/0288587 | Methods of Treating Fibrosis | Pharmaceuticals | Athira Pharma, Inc. |
| Sep 4, 2025 | 2025/0275976 | Methods of Treating Neuroinflammatory Conditions | Pharmaceuticals | Athira Pharma, Inc. |
| Sep 4, 2025 | 2025/0275975 | Methods of Treating Neuropathies | Pharmaceuticals | Athira Pharma, Inc. |
| May 29, 2025 | 2025/0170203 | Methods of Treating Alzheimer's Disease | Pharmaceuticals | Athira Pharma, Inc. |
| May 22, 2025 | 2025/0161308 | Methods of Treating Covid-Related Disorders | Pharmaceuticals | Athira Pharma, Inc. |
| Feb 6, 2025 | 2025/0041307 | Uses of Bicyclic Compounds for the Treatment of Diseases | Pharmaceuticals | Athira Pharma, Inc. |
| Aug 22, 2024 | 2024/0277735 | Methods Of Treating Parkinson’s Disease and/or Lewy Body Disease or Disorder(s) | Pharmaceuticals | Athira Pharma, Inc. |
| Jan 25, 2024 | 2024/0025903 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | Organic fine chemistry | Athira Pharma, Inc. |
| Mar 9, 2023 | 2023/0070758 | Methods of Treating Alzheimer's Disease | Pharmaceuticals | Athira Pharma, Inc. |
| Mar 2, 2023 | 2023/0062006 | Methods of Treating Parkinson's Disease and/or Lewy Body Disease or Disorder(s) | Pharmaceuticals | Athira Pharma, Inc. · patent 11,998,556 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.